We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

1 hedge funds and large institutions have $16K invested in Alexion Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more capital invested

Capital invested by funds: $13K → $16K (+$3K)

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RG
Retirement Group
California
+$262

Top Sellers

No sellers this quarter

ALXN Hedge Fund Activity: Q3 2022 in Review

1 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2022, worth a combined $16K — up 23% from $13K a quarter earlier.

Fund positioning in ALXN was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Retirement Group, adding an estimated $262.

  • 1 institutional investor held Alexion Pharmaceuticals (ALXN) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $16K of Alexion Pharmaceuticals stock for Q3 2022, up 23% quarter-over-quarter.
  • 0 funds opened new Alexion Pharmaceuticals positions in Q3 2022 and 0 closed out.
  • The largest Alexion Pharmaceuticals buyer in Q3 2022 was Retirement Group, an estimated $262 added.

Based on aggregated 13F filings for Q3 2022.